SLC5A2 and hydrops fetalis: SGLT2 inhibitors significantly reduced the composite outcome of HF hospitalization or cardiovascular death,[HR: 0.79 (0.72–0.85); I2 = 0%; P < 0.001]; SGLT2 inhibitors significantly reduced HF hospitalizations.[HR: 0.74 (0.67–0.82); I2 = 0%; P < 0.00001]; SGLT2 inhibitors reduced incidence of any serious adverse events compared to placebo[OR: 0.89 (0.83–0.96); I2 = 0%; P = 0.002]